IceCure Medical (ICCM) announced the promotion of Shay Levav to COO, as the company anticipates accelerating commercial momentum following ProSense’s marketing authorization from the U.S. FDA for low risk breast cancer in October 2025. Levav will continue to lead the company’s Regulatory Affairs, Quality Assurance, and Clinical Affairs, under his new role, that he has overseen since 2020.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure’s Cryoablation System Shows Promising Results in Lung Cancer Treatment
- IceCure Medical Announces Termination of VP of Operations
- Buy Rating for Icecure Medical: FDA Approval and Strategic Initiatives Drive Growth Potential
- IceCure Medical price target raised to $2.50 from $2 at H.C. Wainwright
- IceCure Medical’s ProSense® Receives FDA Approval for Breast Cancer Treatment